Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | triosephosphate isomerase | 0.0091 | 0.7857 | 0.7857 |
Brugia malayi | Proteasome A-type and B-type family protein | 0.007 | 0.4982 | 0.4982 |
Echinococcus granulosus | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Treponema pallidum | triosephosphate isomerase | 0.0091 | 0.7857 | 0.5 |
Entamoeba histolytica | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Schistosoma mansoni | proteasome catalytic subunit 3 (T01 family) | 0.007 | 0.4982 | 0.634 |
Schistosoma mansoni | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Plasmodium falciparum | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Echinococcus multilocularis | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Loa Loa (eye worm) | proteasome A-type and B-type family protein | 0.007 | 0.4982 | 0.4982 |
Loa Loa (eye worm) | hypothetical protein | 0.0073 | 0.5371 | 0.5371 |
Echinococcus multilocularis | proteasome (prosome, macropain) | 0.007 | 0.4982 | 0.634 |
Chlamydia trachomatis | triosephosphate isomerase | 0.0091 | 0.7857 | 0.5 |
Plasmodium falciparum | proteasome subunit beta type-5 | 0.007 | 0.4982 | 0.6129 |
Trypanosoma brucei | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Wolbachia endosymbiont of Brugia malayi | triosephosphate isomerase | 0.0091 | 0.7857 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0107 | 1 | 1 |
Schistosoma mansoni | triosephosphate isomerase | 0.0037 | 0.0429 | 0.0546 |
Echinococcus granulosus | proteasome prosome macropain | 0.007 | 0.4982 | 0.634 |
Toxoplasma gondii | triose-phosphate isomerase TPI-I | 0.0091 | 0.7857 | 1 |
Giardia lamblia | Triosephosphate isomerase, cytosolic | 0.0091 | 0.7857 | 1 |
Mycobacterium leprae | Probable triosephosphate isomerase Tpi (TIM) | 0.0091 | 0.7857 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0073 | 0.5371 | 0.6836 |
Trichomonas vaginalis | triosephosphate isomerase, putative | 0.0091 | 0.7857 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0107 | 1 | 1 |
Trypanosoma cruzi | triosephosphate isomerase, putative | 0.0091 | 0.7857 | 1 |
Mycobacterium tuberculosis | Probable triosephosphate isomerase Tpi (TIM) | 0.0091 | 0.7857 | 1 |
Plasmodium vivax | triosephosphate isomerase, putative | 0.0091 | 0.7857 | 1 |
Plasmodium vivax | proteasome subunit beta type-5, putative | 0.007 | 0.4982 | 0.6129 |
Trichomonas vaginalis | triosephosphate isomerase, putative | 0.0091 | 0.7857 | 1 |
Loa Loa (eye worm) | triosephosphate isomerase | 0.0091 | 0.7857 | 0.7857 |
Mycobacterium ulcerans | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0107 | 1 | 1 |
Toxoplasma gondii | triose-phosphate isomerase TPI-II | 0.0091 | 0.7857 | 1 |
Leishmania major | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0073 | 0.5371 | 0.5371 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI (functional) | = 12 % | Growth inhibition of human MCF7 cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
GI (functional) | = 15 % | Growth inhibition of human A549 cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
GI (functional) | = 22 % | Growth inhibition of human PC3 cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
GI (functional) | = 42 % | Growth inhibition of human OVCAR5 cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
GI (functional) | = 51 % | Growth inhibition of human IMR32 cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
GI (functional) | = 53 % | Growth inhibition of human HeLa cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
GI (functional) | = 62 % | Growth inhibition of human THP1 cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.